

Business Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

JUN 21 2002

PTO/SB/08B (10-01)

Approved for publication by the U.S. Patent and Trademark Office, U.S. Department of Commerce
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Completion if Known

Application Number	09/992.600
Filing Date	November 13, 2001
First Named Inventor	BEJANIN, et al.
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	91.US4.DIV

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
C	B	KIM, S., et al.; "Regulation of Plasminogen Receptor Expression on Monocytoid Cells by B1-Integrin-dependent Cellular Adherence to Extracellular Matrix Proteins"; The Journal of Biological Chemistry; Vol. 271, No. 39, Issue of September 27, pp. 23761-23767, 1996; The American Society for Biochemistry & Molecular Biology, Inc.	
	C	MAO, S., et al.; "Characterization of Plasmin-mediated Activation of Plasma Procarboxypeptidase B"; The Journal of Biological Chemistry, Vol. 274, No. 49, Issue of December 3, pp. 35048-35052, 1999; The American Society for Biochemistry and Molecular Biology, Inc.	
	D	REMINGTON, James S.; "Serine carboxypeptidases: a new and versatile family of enzymes"; Current Opinion in Biotechnology 1993, 4:462-468; Current Biology Ltd.; ISSN 0959-1669	
	E	FRUEBIS, J., et al.; "Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice"; PNAS, February 13, 2001, Vol. 98, No. 4; 2005-2010	
	F	HAMSTRA, D.A., et al.; "Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate- α -peptide prodrugs"; Cancer Research 50, 657-665, February 1, 2000	
	G	MATSUMOTO, A., et al.; "A novel carboxypeptidase B that processes native B-amyloid precursor protein is present in human hippocampus"; European Journal of Neuroscience, Vol. 12, pp. 227-238, 2000; European Neuroscience Association	
	H	HERREN, T., et al.; "Regulation of plasminogen binding to neutrophils"; Blood, 15 February 2001, Vol. 97, No. 4, pp. 1070-1078; The American Society of Hematology	
	I	DU, J., et al.; "Key peptide processing enzymes are expressed by breast cancer cells"; Cancer Letters 165 (2001) 2111-218; 0304-3835/00; Elsevier Science Ireland Ltd.	
	J	NAPIER, M.P., et al.; "Antibody-directed Enzyme Prodrug Therapy: Efficacy and Mechanism of Action in Colorectal Carcinoma"; Clinical Cancer Research, Vol. 6, 765-772, March 2000	
	K	SHI, P.T., et al.; "The solid-phase synthesis of methotrexate- α -peptides"; Yao Xue Xue Bao, 1997; 32(2):106-9; Abstract, PMID: 11243192 [PubMed - indexed for MEDLINE]	
C	L	Accession No. Q96A94; STRAUSBERG, R.	

Examiner
Signature

Cheng

Date

Considered

7-15-01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/992.600	
		Filing Date	November 13, 2001	
		First Named Inventor	BEJANIN, et al.	
		Group Art Unit	1645	
		Examiner Name	Unassigned	
Sheet	3	of	Attorney Docket Number	91.US4.DIV

RECEIVED
JUN 21 2002
TECH CENTER 4600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CM	M	Accession No. Q9HB40; CHO, et al.; "Cloning of novel serine carboxypeptidase precursor"	
	N	Accession No. AAM25395; TANG, et al.; "Isolated human polynucleotides encoding polypeptides, useful for the treatment and diagnosis of e.g. cancer, ulcers and HIV infection"	
	O	Celera Protein Accession No. hCP1766200	
	P	Celera Protein Accession No. hCP46705.2	
	Q	Celera Protein Accession No. hCP1766203	
	R	Accession No. AAY05768; FONG, et al.; "Composition containing human polypeptides with anti-angiogenic activity"	
	S	Accession No. AAY13387; CHEN, et al.; "New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration"	
	T	Accession No. AAY88378; FONG, et al.; "A composition comprising PRO230, PRO216 or PRO302 polypeptides, agonists or antagonists useful for promotion or inhibition of cardiovascularisation, angiogenesis or endothelialisation in mammals"	
	U	Accession No. AAE06595; KATO, et al.; "Human proteins with hydrophobic domains and the nucleic acids encoding them, useful for preventing diagnosing and treating e.g. cancer, Alzheimer's and inflammation"	
	V	Accession No. AAB93913; OTA, et al.; "Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs"	
CM	W	Accession No. AAB20341; Fong, et al.; "Composition comprising a PRO230, PRO216 or PRO302 polypeptide, agonist or antagonist from promoting or inhibiting angiogenesis and/or cardiovascularisation in mammals"	

Examiner Signature	Date Considered
<i>Cooley</i>	<i>7-15-04</i>

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid control number.

RECEIVED
JUN 21 2002

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/992.600
		Filing Date	November 13, 2001
		First Named Inventor	BEJANIN, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
Sheet 4 of 4	Attorney Docket Number	91.US4.DIV	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	X	Accession No. AAB80255; ASHKENAZI, et al.; "Sixty one nucleic acids encoding PRO polypeptides which are useful in the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung squamous cell carcinoma) and neurodegenerative diseases (e.g. Alzheimer's disease)"	
	Y	Accession No. CAC51169; KATO, et al.; "Human proteins having hydrophobic domains and dnas encoding these proteins"	
	Z	Accession No. AF282618; CHO, et al.; "Cloning of novel serine carboxypeptidase precursor"	
	AA	Accession No. AK027373; ISOGAI, et al.; "NEDO human cDNA sequencing project"	
	AB	Accession No. AX191563; KATO, et al.; "Human proteins having hydrophobic domains and dnas encoding these proteins"	

Examiner Signature	<i>Chen</i>	Date Considered	9-15-04
--------------------	-------------	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.